United Therapeutics Corporation (UTHR)
Stock Price Chart
Key Info
| Market Cap | 5.39B |
| Revenue (ttm) | 1.43B |
| Net Income (ttm) | 429.80M |
| Shares Out | 44.41M |
| EPS (ttm) | 9.76 |
| PE Ratio | 12.44 |
| Forward PE | 11.15 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 22, 2020 |
| Last Price | $121.46 |
| Previous Close | $118.85 |
| Change ($) | 2.61 |
| Change (%) | 2.20% |
| Day's Open | 119.34 |
| Day's Range | 119.34 - 121.71 |
| Day's Volume | 252,444 |
| 52-Week Range | 75.58 - 127.79 |
More Stats
| Market Cap | 5.39B |
| Enterprise Value | 4.63B |
| Earnings Date (est) | Oct 28, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 44.41M |
| Float | 43.29M |
| EPS (basic) | 9.79 |
| EPS (diluted) | 9.76 |
| FCF / Share | 13.54 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 8.04% |
| FCF Yield | 11.07% |
| Payout Ratio | n/a |
| Shares Short | 2.04M |
| Short Ratio | 6.94 |
| Short % of Float | 4.70% |
| Beta | 0.71 |
| PE Ratio | 12.44 |
| Forward PE | 11.15 |
| P/FCF Ratio | 9.04 |
| PS Ratio | 3.77 |
| PB Ratio | 1.65 |
| Revenue | 1.43B |
| Operating Income | 554.10M |
| Net Income | 429.80M |
| Free Cash Flow | 597.00M |
| Net Cash | 760.70M |
| Net Cash / Share | 17.13 |
| Gross Margin | 93.03% |
| Operating Margin | 38.72% |
| Profit Margin | 30.00% |
| FCF Margin | 41.72% |
| ROA | 8.55% |
| ROE | 15.21% |
| ROIC | 15.80% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,449 | 1,628 | 1,725 | 1,599 | 1,466 | 1,289 | 1,117 | 916 | 743 | 593 |
| Revenue Growth | -11% | -5.65% | 7.91% | 9.07% | 13.76% | 15.36% | 21.93% | 23.26% | 25.35% | - |
| Gross Profit | 1,331 | 1,429 | 1,620 | 1,526 | 1,397 | 1,163 | 986 | 797 | 654 | 525 |
| Operating Income | -188 | 805 | 815 | 1,062 | 699 | 539 | 292 | 422 | 318 | 171 |
| Net Income | -105 | 589 | 418 | 714 | 652 | 340 | 175 | 304 | 218 | 106 |
| Shares Outstanding | 43.80 | 43.50 | 44.00 | 43.80 | 46.00 | 48.20 | 50.08 | 52.09 | 57.16 | 56.14 |
| Earnings Per Share | -2.39 | 13.39 | 9.31 | 15.25 | 12.72 | 6.28 | 3.28 | 5.71 | 3.67 | 1.78 |
| EPS Growth | - | 43.82% | -38.95% | 19.89% | 102.55% | 91.46% | -42.56% | 55.59% | 106.18% | - |
| Operating Cash Flow | -207 | 778 | 474 | 644 | 383 | 355 | 425 | 324 | 250 | 212 |
| Capital Expenditures | -83.70 | -184 | -78.00 | -38.00 | -49.80 | -47.40 | -31.91 | -112 | -35.98 | -18.64 |
| Free Cash Flow | -290 | 594 | 396 | 606 | 333 | 308 | 393 | 212 | 214 | 193 |
| Cash & Equivalents | 1,486 | 1,416 | 927 | 1,051 | 954 | 696 | 694 | 479 | 403 | 627 |
| Total Debt | 850 | 250 | 250 | - | - | 126 | 282 | 276 | 266 | 305 |
| Net Cash / Debt | 636 | 1,166 | 677 | 1,051 | 954 | 569 | 411 | 203 | 138 | 322 |
| Assets | 3,913 | 3,401 | 2,879 | 2,326 | 2,184 | 1,884 | 2,088 | 1,627 | 1,518 | 1,432 |
| Liabilities | 1,133 | 593 | 758 | 463 | 585 | 619 | 783 | 532 | 559 | 537 |
| Book Value | 2,780 | 2,789 | 2,102 | 1,851 | 1,589 | 1,242 | 1,259 | 1,084 | 948 | 884 |
Company Profile
Company Details
| Full Name | United Therapeutics Corporation |
| Country | United States |
| Employees | 920 |
| CEO | Martine A. Rothblatt |
Stock Information
| Ticker Symbol | UTHR |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: UTHR |
| IPO Date | June 17, 1999 |
Description
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.